Business Development

At Unlearn, our purpose is to advance artificial intelligence (AI) to eliminate trial and error in medicine. We are innovating advanced machine learning methods to leverage generative AI in forecasting patient outcomes, starting with the domain of clinical trials. We produce AI-generated digital twins of individual trial participants, enabling smaller and more efficient clinical trials to bring effective medicines to patients sooner.

Our innovative work in AI today will reinvent how AI is applied in medicine tomorrow — and we have a top secret plan for how to get there. We won’t be able to achieve this mission just by applying technologies created by others; the future must be invented.

Unlearn is a technology company, not a biotech company. We use computers, not pipettes. We make and use software, we don’t discover or make drugs. We believe that AI will define the future of medicine, and we aren’t deterred by naysayers or skeptics. 

We come from a variety of backgrounds ranging from machine learning to marketing—but regardless of where we come from, Unlearners share some common traits:

• Unlearners are ambitious; we aren’t intimidated by big, challenging goals. 

• Unlearners are disciplined experimenters; we break down our big goals into smaller chunks and meet as often as necessary to track our velocity and iterate quickly. 

• Unlearners are gritty; we never give up, setbacks just make us try harder.

• Unlearners are receptive to new ideas; in fact, we hate being stuck with the status quo

• Unlearners are storytellers; sharing information with each other and with the world is super important, too important to be boring.  And, last but not least,

• Unlearners are team-oriented; we put the mission first, the company second, the team third, and individuals last.

Headquartered in San Francisco, with an additional office in Boston, Unlearn was founded in 2017 by a team of world-class machine learning scientists.  We have raised venture capital from top tier investors such as Altimeter, Insight Partners, Radical Ventures, 8VC, DCVC, and DCVC Bio, and recently completed our $50 million Series C in January 2024.

If our purpose and culture resonate with you, we invite you to apply.

The Role 

Unlearn is looking for an experienced business development professional who is passionate about driving change in the pharmaceutical industry by selling AI-driven partnerships to clinical development teams.

Reporting to the …